

ASX Announcement

Azer-cel accepted for presentation at ASTCT Tandem Meetings event

SYDNEY, Australia, 20 December 2024: Imugene Limited (ASX:IMU), a clinical-stage immuno-oncology company, is pleased to announce that an abstract regarding its allogeneic CAR T-cell therapy azer-cel has been accepted for a poster presentation at the upcoming 2025 Tandem Meetings event for the Transplantation & Cellular Therapy Meetings of ASTCT (American Society for Transplantation and Cellular Therapy) and CIBMTR (Center for International Blood and Marrow Transplant Research).

The event will be held 12–15 February 2025 in Hawaii, USA.

The abstract for the poster will be available for viewing on Friday 17 January 2025 and all details will be posted on Imugene's website at

<https://imugene.com/investors/conference-presentations/>

Abstract title: Administration of Low-Dose, Subcutaneous (SC) Interleukin-2 (IL-2) Markedly Enhances the Pharmacokinetic (PK) Profile of Azercabtagene Zapreleucel (azer-cel), an Allogeneic Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, without Compromising Safety and Early Evidence of Clinical Activity in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Have Relapsed after Prior CD19-Directed CAR T-Cell Products

Poster Session: Engineered Immune Cells (CAR-T, NK, TCR): Clinical – Immune Effector Cells for Heme Malignancies, Thursday, February 13, 2025, 6:45 PM

Presenting author: Dr Joseph Maakaron, Assistant Professor of Medicine, Division of Hematology, Oncology, and Transplantation at the University of Minnesota

The ASTCT Tandem Meetings event highlights the latest research and breakthroughs in hematopoietic cell transplantation (HCT), cellular therapy and gene therapy.



For more information please contact:

Leslie Chong

Managing Director and Chief Executive Officer

info@imugene.com

General Investor Enquiries

shareholderenquiries@imugene.com

Media Enquiries

Matt Wright

matt@nwrcommunications.com.au

Connect with us on LinkedIn @Imugene Limited

Follow us on Twitter @TeamImugene

Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.

Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading



specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.